| Name | Title | Contact Details |
|---|
Abilities Inc. is one of the leading providers in Business Services. It is based in Albertson, NY. To find more information about Abilities Inc., please visit www.abilitiesonline.org.
At Thynkli, we design and build a Digital Twin of an Organization that perfectly improves operational processes. Take the digital maturity assesment to find out where your organizations stands.
A purpose-driven company since June 15th, Clariane is the leading European community for care in times of vulnerability. Our Groups purpose « To take care of each persons humanity in times of vulnerability » is inspired by our three core values: trust, responsibility and initiative. With our facilities located in the heart of 700 localities in 7 European countries, we are committed to working alongside vulnerable people, to be present wherever they need us. Our expertise? Delivering our Positive Care approach through 3 areas of activity: - Care homes – we care - Healthcare facilites and services – we cure - Alternative living solutions – we welcome and enliven. Relying on their diverse expertise, each year, our community unites, trains and supports around 70,000 professionals who provide services to over 800,000 patients and residents in three main areas of activity: long-term care nursing home (Korian, Seniors Residencias, Berkley, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, Lebenswert, etc.), and alternative living solutions (Petits-fils, Les essentiels, Ages et Vie, etc.). Our actions are guided every day by 5 key commitments: consideration, equity, innovation, proximity and sustainability Our Clariane community: at your side, at every moment. #ClarianeAtYourSide #WeAreClariane #PurposeDrivenCompany
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The companys initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Enshos assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the companys pipeline.
Design Quest is a Natick, MA-based company in the Business Services sector.